BONITA SPRINGS, Fla.--(BUSINESS WIRE)--April 6, 2006--Tigris Pharmaceuticals, Inc., a development stage biopharmaceutical company, announced the initiation of a multi-center, double-blind Phase II clinical trial with A-007 in 250 patients with high-grade cervical intraepithelial neoplasia (CIN).
